Food and Drug Administration

Antiviral Drugs Advisory Committee

May 13, 2003




The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Atazanavir NDA 21-567, FDA (HTM) (PPT)

Evaluation of Cardiac Safety by ECG Findings: Focus on QTc Duration, Dr. Joel Morganroth, MD (HTM) (PPT)

Atazanavir (ATV, BMS-232632), Bristol-Myers Squibb, Co. (PDF)

Backup Information, Brostol-Myers Squibb, Co. (HTM) (PPT)

Atazanavir, Medical Review, Dr. Kendall Marcus, MD, FDA (HTM) (PPT)